F/M Emerald Life Sciences Innovation ETF (LFSC)

Assets	$128.07M
Expense Ratio	0.54%
PE Ratio	n/a
Shares Out	2.75M
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	1,772
Open	47.33
Previous Close	47.18
Day's Range	46.82 - 47.35
52-Week Low	26.75
52-Week High	47.68
Beta	n/a
Holdings	40
Inception Date	Oct 31, 2024

About LFSC

Fund Home Page

The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: NASDAQ
• Ticker Symbol: LFSC
• ETF Provider: F/m Investments

Top 10 Holdings

55.99% of assets

Name	Symbol	Weight
Travere Therapeutics, Inc.	TVTX	8.64%
Spyre Therapeutics, Inc.	SYRE	7.68%
Cogent Biosciences, Inc.	COGT	7.66%
Corcept Therapeutics Incorporated	CORT	6.34%
LivaNova PLC	LIVN	6.22%
Guardant Health, Inc.	GH	5.71%
Cytokinetics, Incorporated	CYTK	3.97%
United Therapeutics Corporation	UTHR	3.39%
BillionToOne, Inc.	BLLN	3.20%
Axsome Therapeutics, Inc.	AXSM	3.20%

Performance

LFSC had a total return of 77.74% in the past year, including dividends. Since the fund's inception, the average annual return has been 42.13%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Aug 13, 2026

Data Sources Report a data error